AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29594201
Drug: Lung FDG
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung FDG uptake (measured by SUVmax, SUVmean, SUVpeak, and GLG) after concurrent chemoradiation (CRT)
Trial: 29594970
Drug: Anti-TNF agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF agents (monotherapy or combination)
Trial: 29595064
Drug: Venetoclax monotherapy;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax monotherapy; specific dosage and duration not mentioned.
Trial: 29595064
Drug: Venetoclax followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax followed by the addition of chemotherapy; specific chemotherapy regimen not mentioned.
Trial: 29598861
Drug: Conventional Biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Biological Valves (CBV)
Trial: 29598891
Drug: Open surgical
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgical treatment (all patients combined)
Trial: 29599068
Drug: Diuretic exposure
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic exposure
Trial: 29599068
Drug: No diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No diuretic exposure (Control)
Trial: 29599200
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment (specifics not provided)
Trial: 29599200
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow transplantation (consolidation treatment)
Trial: 29600824
Drug: Norepinephrine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine monotherapy
Trial: 29601256
Drug: MenABCWY+OMV booster
RxNorm normalized name: Omvoh
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenABCWY+OMV booster (1 dose for Group III, 2 doses for Groups VI and VII)
Trial: 29601256
Drug: MenABCWY+OMV (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenABCWY+OMV (2 doses)
Trial: 29601268
Drug: Concurrent aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent aerobic and strength training, three 60-minute sessions per week from the 17th gestational week until delivery
Trial: 29602767
Drug: Dual loading
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual loading antiplatelet therapy with aspirin and P2Y
Trial: 29603015
Drug: Ulixertinib (BVD-523)
RxNorm normalized name: BVdU
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulixertinib (BVD-523) at a recommended phase 2 dose of 600 mg BID
Trial: 29603017
Drug: Home-wearable light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-wearable light therapy for 60 min daily for 5 weeks
Trial: 29603017
Drug: Home-wearable light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-wearable light therapy
Trial: 29603764
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose lenalidomide (10 mg) plus dexamethasone (Rdex)
Trial: 29605216
Drug: High ICS
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ICS doses
Trial: 29606148
Drug: Standard Speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Speech and Language Therapy (usual care)
Trial: 29606415
Drug: Alirocumab 75mg
RxNorm normalized name: ALIROCUMAB 75MG/ML INJ 1ML SYR
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alirocumab 75mg every 2 weeks (Q2W) added to statin therapy (atorvastatin ≥10mg/day or rosuvastatin ≥5mg/day), with a potential increase to 150mg Q2W if LDL-C remains ≥100mg/dL at week 12.
Trial: 29606415
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) with atorvastatin ≥10mg/day or rosuvastatin ≥5mg/day, with dose adjustment to achieve LDL-C <100mg/dL.
Trial: 29606586
Drug: Larotrectinib, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotrectinib, administered orally (capsule or liquid), twice daily on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. Doses included 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2).
Trial: 29606665
Drug: Combination ETN
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ETN plus csDMARD
Trial: 29607050
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg UDCA for 12 weeks followed by 50 mg sitagliptin for 12 weeks (UDCA-first group)
Trial: 29607050
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sitagliptin for 12 weeks followed by 900 mg UDCA for 12 weeks (sitagliptin-first group)
Trial: 29607050
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg UDCA
Trial: 29608587
Drug: Flolan (epoprostenol)
RxNorm normalized name: epoprostenol Injection [Flolan]
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flolan (epoprostenol) solution prepared with the reformulated pH 12.0 diluent
Trial: 29608587
Drug: Flolan (epoprostenol)
RxNorm normalized name: epoprostenol Injection [Flolan]
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flolan (epoprostenol) solution prepared with the existing pH 10.5 diluent
Trial: 29609013
Drug: Bimekizumab (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab (64 mg, 160 mg, 320 mg, 480 mg)
Trial: 29609532
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) discontinuation with regular monitoring
Trial: 29610115
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2), Lenalidomide, Ibrutinib
Trial: 29610121
Drug: ERBB3-Directed Targeted
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERBB3-Directed Targeted Therapy
Trial: 29610659
Drug: CCLG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCLG group (chemotherapy with less local treatment)
Trial: 29610659
Drug: GPOH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPOH group (chemotherapy with more local treatment)
Trial: 29611022
Drug: GSK2141795 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2141795 (75 mg daily)
Trial: 29614955
Drug: G allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G allele of SNP rs2528795 in ELN gene
Trial: 29614997
Drug: Study-specific questionnaires
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study-specific questionnaires measuring level of knowledge about disease and treatment.
Trial: 29616236
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control group (monthly household visits to measure child mid-upper arm circumference)
Trial: 29617001
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (personalized based on ARR10 benefit threshold)
Trial: 29617001
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (personalized based on ARR10 benefit threshold ≥2.3%)
Trial: 29617822
Drug: Dolutegravir maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir maintenance monotherapy
Trial: 29618159
Drug: New generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generation P2Y12 inhibitors
Trial: 29619634
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 3 grams daily
Trial: 29622037
Drug: SAM-760 30
RxNorm normalized name: SAM
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM-760 30 mg once daily for 12 weeks
Trial: 29622159
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation at discharge
Trial: 29622168
Drug: Low-Dose Ticagrelor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Ticagrelor
Trial: 29622168
Drug: Standard-Dose Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-Dose Ticagrelor
Trial: 29622527
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (weekly phone-based notifications)
Trial: 29622755
Drug: Febuxostat (xanthine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (xanthine oxidase inhibitor) for 6 months, lowering serum UA to <6 mg/dL
Trial: 29622755
Drug: Febuxostat (xanthine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (xanthine oxidase inhibitor) for 6 months
Trial: 29624558
Drug: Cefixime 800
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime 800 mg
Trial: 29624558
Drug: Cefixime 1200
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime 1200 mg
Trial: 29624558
Drug: Cefixime 800
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime 800 mg every 8 hours × 3 doses (total dose 2400 mg)
Trial: 29624882
Drug: No vaccine
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vaccine coverage
Trial: 29625571
Drug: Automated telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated telephone self-management (ATSM) queries for diabetes, blood pressure, and cholesterol pills
Trial: 29625579
Drug: Self-matching to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-matching to treatment options
Trial: 29625579
Drug: Expert-matching to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expert-matching to treatment options
Trial: 29625622
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (standard hospital treatment)
Trial: 29626135
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of multiple burr hole procedure under local anesthesia and intravenous erythropoietin pretreatment
Trial: 29628312
Drug: ALT-803 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALT-803 (20 μg/kg subcutaneously once per week) in combination with nivolumab (240 mg intravenously every 14 days)
Trial: 29628397
Drug: Enhanced labile
RxNorm normalized name: Eucalyptus Leaf (Eucalyptus Globulus Labill.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced labile plasma iron (eLPI) measured in serum samples with the FeROS eLPI kit; values greater than 0.4 μmol/L considered raised eLPI.
Trial: 29628397
Drug: eLPI as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eLPI as a biological mediator of iron-related toxicity.
Trial: 29629190
Drug: Antibiotic awareness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic awareness activities
Trial: 29629190
Drug: Proxy indicators
RxNorm normalized name: proxyphylline
DrugBank: Proxyphylline (DB13449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxy indicators for detecting problematic antibiotic behaviours
Trial: 29630018
Drug: Any medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any medication taken during pregnancy
Trial: 29630018
Drug: Any medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any medication taken in the first trimester
Trial: 29630018
Drug: Polypharmacy (taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (taking at least five medications)
Trial: 29630018
Drug: Medications taken
RxNorm normalized name: salicylic acid Medicated Liquid Soap [Take Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications taken during pregnancy (excluding vitamins, supplements, and vaccines)
Trial: 29630018
Drug: Medications taken
RxNorm normalized name: salicylic acid Medicated Liquid Soap [Take Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications taken in the first trimester (excluding vitamins, supplements, and vaccines)
Trial: 29630018
Drug: Gastrointestinal or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrointestinal or antiemetic agents
Trial: 29631584
Drug: Circulating sex
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Circulating sex hormones (testosterone, DHEA-S, estrogen, progesterone)
Trial: 29631615
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow mesenchymal stem cell (BMMSC) transplantation therapy
Trial: 29632533
Drug: M72/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M72/AS01 vaccine administered in two doses (30 days apart)
Trial: 29632720
Drug: PD-1 blockade
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 blockade (knockout or antibody blockade)
Trial: 29635415
Drug: PrEP (preexposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP (preexposure prophylaxis) offered to participants; specific dosage and duration not mentioned.
Trial: 29635876
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) therapy at a maintenance dose of 1.0 g/kg every 3 weeks for 52 weeks.
Trial: 29636030
Drug: Two-stage surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage surgical strategy (debridement-negative pressure therapy and flap coverage) with prolonged antimicrobial therapy
Trial: 29636042
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of insulin, having some problems with T2D self-care, coffee consumption
Trial: 29636983
Drug: Hip muscle
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip muscle strengthening and core stabilization program (10 sessions, twice a week for 6 weeks)
Trial: 29636984
Drug: Daily protein
RxNorm normalized name: Supra Clens Daily Protein Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily protein supplement (120 mmol of solutes, allowing an extra 163 mL free water loss) for 4 weeks
Trial: 29636984
Drug: Daily protein
RxNorm normalized name: Supra Clens Daily Protein Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily protein supplement
Trial: 29637088
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (minimum 12 hours) followed by oral antibiotics (total course 10 days)
Trial: 29638161
Drug: High Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High Insulin Studies (HISs)
Trial: 29638161
Drug: Low Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low Insulin Studies (LISs)
Trial: 29641297
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg on a 2/1 schedule
Trial: 29641374
Drug: Medication monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication monitoring sensors
Trial: 29643053
Drug: Mobile app
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile app intervention with daily questionnaires
Trial: 29643063
Drug: Prexasertib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prexasertib, a Checkpoint Kinase 1 Inhibitor
Trial: 29645077
Drug: Risk model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk model for predicting colorectal cancer (CRC) based on clinical characteristics including rectal bleeding, weight loss, and changes in bowel habits.
Trial: 29645077
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rectal bleeding with weight loss and changes in bowel habits.
Trial: 29649027
Drug: Pain interference
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain interference with daily life
Trial: 29649885
Drug: S-amlodipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-amlodipine 2.5 mg/d
Trial: 29649885
Drug: S-amlodipine 5
RxNorm normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-amlodipine 5 mg/d
Trial: 29649885
Drug: Previous antihypertensive
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous antihypertensive medications
Trial: 29650362
Drug: Tazemetostat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazemetostat (100 mg to 1600 mg twice daily)
Trial: 29650362
Drug: Tazemetostat (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazemetostat (800 mg twice daily)
Trial: 29652795
Drug: HIV protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV protease inhibitor (PI)
Trial: 29653643
Drug: High-density lipoprotein
RxNorm normalized name: Cholesterol in High-density lipoprotein (HDL) 2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-density lipoprotein cholesterol levels >40 mg/dL for men and >50 mg/dL for women
Trial: 29653643
Drug: Glucose levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose levels <100 mg/dL
Trial: 29654023
Drug: Gemcitabine-included doublet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine-included doublet chemotherapy
Trial: 29654485
Drug: Tocilizumab (TCZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (TCZ), 8 mg/kg, intravenous infusion every 4 weeks
Trial: 29654720
Drug: Anticoagulant use
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant use
Trial: 29655061
Drug: Chemotherapy ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy ± maintenance endocrine therapy
Trial: 29655489
Drug: Cochleural Alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochleural Alternating Acoustic Beam Therapy (CAABT) for 12 weeks
Trial: 29655662
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin anti-coagulation (INR target 1.5 to 1.9)
Trial: 29655877
Drug: Spironolactone 25-50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25-50 mg
Trial: 29655877
Drug: Amiloride 10-20
RxNorm normalized name: amiloride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 10-20 mg
Trial: 29655877
Drug: Bisoprolol 5-10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5-10 mg
Trial: 29655877
Drug: Doxazosin 4-8
RxNorm normalized name: doxazosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4-8 mg
Trial: 29656846
Drug: NDI-G
RxNorm normalized name: NDI-5001
DrugBank: NDI-5001 (DB17609)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDI-G
Trial: 29657831
Drug: Verinurad 2.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 2.5-20 mg in combination with febuxostat (40 or 80 mg)
Trial: 29657831
Drug: Febuxostat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (40 or 80 mg) alone
Trial: 29657831
Drug: Verinurad administered
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad administered with febuxostat
Trial: 29658848
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) administered intravenously every 2 weeks for 2 doses before surgery
Trial: 29658962
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing 291 kcal/d for young children and 350 kcal/d for older children, administered 5 days/week for 11 weeks.
Trial: 29659102
Drug: Antidepressants for
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants for GAD
Trial: 29659102
Drug: Antidepressants for
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants for PD
Trial: 29659102
Drug: Antidepressants for
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants for SAD
Trial: 29659102
Drug: Antidepressants for
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants for OCD
Trial: 29659102
Drug: Antidepressants for
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants for PTSD